16234-15-4 2-氯-4-(4-吗啉基)噻吩并[3,2-D]嘧啶

中文名称: 2-氯-4-(4-吗啉基)噻吩并[3,2-D]嘧啶
英文名称: 4-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)morpholine
CAS号
分子式: C₁₀H₁₀ClN₃OS
分子量: 255.72
更新日期: 2026-06-23

名称和标识

中文名: 2-氯-4-(4-吗啉基)噻吩并[3,2-D]嘧啶
英文名: 4-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)morpholine
CAS号: 16234-15-4
分子式: C10H10ClN3OS
分子量: 255.72
中文别名: 2-氯-4-(吗啉-4-基)噻吩并[3,2-D]嘧啶; 噻吩并[3,2-D]嘧啶, 2-氯-4-(4-吗啉基)-; 4-{2-氯噻吩并[3,2-D]嘧啶-4-基}吗啉; 4-(2-氯噻吩[3,2-D]嘧啶-4-基)吗啉
英文别名: 2-Chloro-4-(morpholin-4-yl)thieno[3,2-d]pyrimidine; 2-Chloro-4-(4-morpholinyl)thieno[3,2-d]pyrimidine; 2-chloro-4-Morpholinothieno[3,2-d]pyrimidine; Thieno[3,2-d]pyrimidine, 2-chloro-4-(4-Morpholinyl)-; 4-{2-chlorothieno[3,2-d]pyrimidin-4-yl}morpholine; 2-chloro-4-(morpholin-4-yl)-thieno[3,2-d]pyrimidine; 2-Chloro-4-morpholinothienon[3,2-d]pyrimidine; 2-chloro-4-morpholine-4-yl-thieno[3,2-d]pyrimidine; 2-Chlor-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin

物化属性

Log S: -3.42
LogP: 2.22
MLOGP: 1.44
PSA: 66.49 Å²
SILICOS-IT LogP: 3.19
WLOGP: 1.8
XLogP3: 2.61
iLOGP: 2.65
密度: 1.5±0.1 g/cm³
折射率: 1.671
沸点: 393.7±42.0 °C (760 mmHg)
溶解度: 0.0972 mg/ml
蒸汽压: 0.0±0.9 mmHg (25 °C)
酸度系数(pKa): 3.82±0.40 (Predicted)
闪点: 191.9±27.9 °C

安全信息

安全说明

海关编码:2933399990

生产及用途

用途与制备

2-氯-4-(4-吗啉基)噻吩并[3,2-D]嘧啶为嘧啶类衍生物，可用作医药化工中间体。
制备以噻吩并[3,2-d]嘧啶-2,4-二醇为起始物料，经氯代反应制备得到目标化合物2,4-二氯-噻吩[3,2-D]嘧啶，后与吗啉发生取代反应制备得到目标化合物2-氯-4-(4-吗啉基)噻吩并[3,2-D]嘧啶。其合成反应式如下图：

医药化工

合成路线 1（1. 合成：16234-15-4）

产率：100% 合成条件：at 20℃; for 1 h; 实验步骤：参考实施例2：2-氯-4-吗啉-4-基 - 噻吩并[3,2-d]嘧啶（65）（65）2,4-二氯 - 噻吩并[3,2-d]嘧啶（64）的混合物，（将8.68g，42.34mmol），吗啉（8.1mL，2.2当量）和MeOH（150mL）在室温下搅拌1小时。然后过滤反应混合物，用水和MeOH洗涤，得到标题化合物，为白色固体（11.04g，100％）。 EPO 1H NMR（400MHz，J6-DMSO）3.74（4H，t，J = 4.9Hz），3.90（4H，t，J = 4.9Hz），7.40（1H，d，J = 5.6Hz），8.30（IH），d，J = 5.6Hz）。 参考文献：

[1] Patent: WO2006/46031, 2006, A1. Location in patent: Page/Page column 29-30 [2] Patent: US2008/76768, 2008, A1. Location in patent: Page/Page column 7 [3] Patent: US2008/76758, 2008, A1. Location in patent: Page/Page column 73 [4] Patent: WO2008/70740, 2008, A1. Location in patent: Page/Page column 133 [5] Patent: WO2008/73785, 2008, A2. Location in patent: Page/Page column 160 [6] Patent: WO2009/53715, 2009, A1. Location in patent: Page/Page column 64 [7] Patent: US2010/233164, 2010, A1 [8] Patent: WO2011/130628, 2011, A1. Location in patent: Page/Page column 129 [9] Patent: US2013/102595, 2013, A1. Location in patent: Paragraph 0176 [10] Patent: US9335320, 2016, B2. Location in patent: Page/Page column 70; 71 [11] Patent: JP2015/187145, 2015, A. Location in patent: Paragraph 0174 [12] Patent: JP5658565, 2015, B2. Location in patent: Paragraph 0334-0335 [13] Patent: WO2007/122410, 2007, A1. Location in patent: Page/Page column 62-63 [14] Patent: WO2007/127183, 2007, A1. Location in patent: Page/Page column 135-136 [15] Patent: WO2017/90058, 2017, A1. Location in patent: Page/Page column 17 [16] Chemical and Pharmaceutical Bulletin, 2012, vol. 60, # 8, p. 1037 - 1045 [17] European Journal of Medicinal Chemistry, 2012, vol. 57, p. 162 - 175 [18] European Journal of Medicinal Chemistry, 2015, vol. 93, p. 64 - 73 [19] Organic Process Research and Development, 2013, vol. 17, # 1, p. 97 - 107 [20] Patent: US9249156, 2016, B2. Location in patent: Page/Page column 37 [21] Patent: WO2018/85342, 2018, A1. Location in patent: Page/Page column 25; 30; 31 [22] European Journal of Medicinal Chemistry, 2018, vol. 151, p. 836 - 848 [23] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 8, p. 2408 - 2411 [24] Patent: US2011/230476, 2011, A1. Location in patent: Page/Page column 247 [25] Chinese Chemical Letters, 2012, vol. 23, # 6, p. 703 - 706 [26] Journal of Medicinal Chemistry, 2012, vol. 55, # 17, p. 7686 - 7695 [27] Patent: US2011/269244, 2011, A1. Location in patent: Page/Page column [28] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 1, p. 358 - 365 [29] Patent: CN103980287, 2016, B. Location in patent: Paragraph 0117; 0122; 0123 [30] Patent: CN104292242, 2017, B. Location in patent: Paragraph 0123; 0124; 0125

词条详情加载中…